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Abstract: Longevity is determined by a number of factors, including genetic, environmental and
lifestyle factors. A major factor affecting longevity is the development of degenerative disorders such
as cardiovascular disease, diabetes, kidney disease and liver disease, particularly where these occur
as co-morbidities. In this article, we review the potential role of supplementation with coenzyme
Q10 (CoQ10) for the prevention or management of these disorders. Thus, randomised controlled
clinical trials have shown supplementation with CoQ10 or CoQ10 plus selenium reduces mortality
by approximately 50% in patients with cardiovascular disease, or in the normal elderly population,
respectively. Similarly, CoQ10 supplementation improves glycaemic control and vascular dysfunction
in type II diabetes, improves renal function in patients with chronic kidney disease, and reduces liver
inflammation in patients with non-alcoholic fatty liver disease. The beneficial role of supplemental
CoQ10 in the above disorders is considered to result from a combination of its roles in cellular energy
generation, as an antioxidant and as an anti-inflammatory agent.
Keywords: coenzyme Q10; oxidative stress; inflammation; diabetes; cardiovascular disease; chronic
kidney disease and liver disease; mitochondria
1. Introduction
Longevity depends on a number of factors, one of the most important determinants being the
development of chronic degenerative diseases, particularly where these occur as co-morbid conditions.
For example, a 70-year old individual with no chronic degenerative diseases will be expected to
live for more than 20 years, whereas those with several such disorders would be predicted to live
some 8 years fewer [1]. In the present article, we have reviewed how oral supplementation with
coenzyme Q10 (CoQ10) may significantly benefit degenerative disorders such as cardiovascular
disease, diabetes, kidney disease and liver disease, thereby promoting longevity. The rationale for
CoQ10 supplementation in these disorders is based on its key role in cellular metabolism; in addition
to its role in cellular energy generation, CoQ10 has antioxidant and anti-inflammatory action (Figure 1),
is involved in DNA replication and repair (through its essential cofactor role in pyrimidine synthesis),
regulates the physiochemical properties of cellular membranes, and modulates gene expression [2].
Meta-analyses of clinical studies have demonstrated that supplementation with CoQ10 significantly
reduces levels of the inflammatory mediators C-reactive protein (CRP), interleukin-6 (IL-6) and tumour
necrosis factor alpha (TNF-α) respectively [3,4]. Schmelzer et al. [5] had previously provided evidence
that levels of inflammatory mediators such as CRP, IL-6 and TNF-α are reduced via the effect of
supplementary CoQ10 on the nuclear transcription factor NF kappa beta. Most of the body’s daily
CoQ10 requirement is derived from endogenous synthesis [6], and this is known to decline substantially
with age [7]. This age-related decline in endogenous CoQ10 synthesis may therefore be directly linked
to longevity via the development of these degenerative disorders [8].
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2. Cardiovascular Disease
The role of CoQ10 supplementation in the treatment or prevention of cardiovascular disease
has been detailed in previous reviews [9,10]. Although there is a distinct lack of high quality
studies assessing the utility of CoQ10 supplementation in the primary prevention of cardiovascular
disease [11], two recently published randomised, double blind, placebo controlled clinical trials have
demonstrated the efficacy of supplementation with CoQ10 (Q-SYMBIO) or CoQ10 plus selenium
(KISEL-10) in substantially reducing mortality risk in patients with heart failure, or in the normal
elderly population, respectively.
The Q-SYMBIO study was carried out in some 400 patients with chronic heart failure (New York
Heart Association; NYHA class III or IV), and the effect of CoQ10 supplementation (3× 100mg/day for
two years) on symptoms and biomarker status (hence the trial acronym Q-SYMBIO) were assessed [12].
Assessment included clinical examination, echocardiography and pro-BNP(B-type natriuretic peptide)
status (a biomarker related to cardiac wall tension and ejection fraction, used to quantitate heart
failure). The primary long-term endpoint was time to first major adverse cardiovascular event (MACE),
which included unplanned hospitalisation due to worsening heart failure and cardiovascular death.
Supplementation with CoQ10 reduced the risk of MACE by 42%, with a reduction of
approximately 40% in both cardiac related deaths and all-cause mortality. There was no significant
difference in adverse events between the CoQ10 treated and placebo groups over the duration of the
study. CoQ10 has therefore been reported as the first novel drug (i.e., one addressing cardiac myocyte
energy depletion) to improve heart failure mortality in over a decade.
The KISEL-10 study was a double blind, randomised, placebo controlled clinical trial carried out
on normal elderly individuals (70–88yrs) from the Kinda region of Stockholm [13]; 440 participants
were supplemented with 200 mg/day coenzyme Q10 (CoQ10; Bio-Quinone 100mg) and 200 mcg/day
selenium (SelenoPrecise), or placebo, over a five year period (hence the trial acronym KISEL-10).
Clinical examination, echocardiography and biomarker measurements were carried out at six-month
intervals. Supplementation with CoQ10 and selenium resulted in significant reductions in the blood
levels of pro-BNP [14], C-reactive protein and, soluble platelet selectin (sP selectin) as markers of
inflammation [15], and copeptin and adrenomedullin as markers of oxidative stress [16]. Quality of life
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was quantified using the Short Form-36 (SF-36), Cardiac Health Profile (CHP) and Overall Quality of
Life (overall-QOL) questionnaires. Supplementation resulted in a significant reduction in the number
of days in hospital and significantly slowed the deterioration in health related quality of life [17].
Echocardiography showed significantly better cardiac function in supplemented participants, whose
risk of cardiovascular mortality was significantly reduced by 53% [14]. It is of note that a follow-up
study showed the protective effect of CoQ10 and selenium supplementation in reducing the risk of
cardiovascular mortality persisted for several years after the end of the intervention period [18].
The KISEL-10 study demonstrated long-term supplementation with CoQ10 and selenium
significantly improved quality of life and heart function, and reduced hospitalisation frequency
and the risk of cardiovascular related mortality in the elderly. At a mechanistic level, the benefits
of supplementation with CoQ10 and selenium are derived both from their role in cellular energy
production, and as tissue protecting antioxidants. Supplementation with CoQ10 and selenium may
be of particular benefit for individuals prescribed statins, since the latter are known to interfere in
the production of both CoQ10 and selenoproteins such as thioredoxin reductase and glutathione
peroxidase [19]. Thioredoxin reductase is responsible for the interconversion of ubiquinone to
ubiquinol, and glutatione peroxidase is an important antioxidant enzyme.
The KISEL-10 study supplemented two nutrients, CoQ10 and selenium, with a key role in heart
function, which were also likely to be deficient in the elderly population investigated. In the case of
CoQ10, most of the body’s daily requirement is obtained by endogenous synthesis. As people age,
the capacity for endogenous synthesis declines, such that blood CoQ10 levels in a 65 year old are
approximately half that in a 25 year old. With regard to selenium, dietary intake in many European
countries, including Sweden and the UK, is known to be sub-optimal, particularly in the elderly. The
above provides a rationale for the success of the KISEL-10 protocol in reducing the risk of death from
heart disease.
Amongst the normal elderly Swedish population, those with the lowest levels of blood selenium
were found to be at increased risk of cardiovascular mortality [20]. The age-related decline in
endogenous CoQ10 synthesis, sub-optimal dietary intake of selenium and associated increased risk of
heart disease and cardiovascular mortality therefore provided the rationale for the supplementation
regime employed in the KISEL-10 study.
3. Diabetes
The potential benefit of CoQ10 supplementation in type II diabetes has been recently reviewed [21],
from which the following information has been summarized. Firstly, a number of studies have
identified depleted blood CoQ10 levels in patients with type II diabetes, an example being the study
by El-Ghoroury et al. [22].
Some 15 randomised controlled clinical trials supplementing CoQ10 (typically 100–200 mg/day
for 3–6 months) in type II diabetic patients are currently listed by Medline. Although Eriksson et
al. [23] found no significant benefit of CoQ10 supplementation on glycaemic control in type II diabetics,
subsequent studies reported CoQ10 supplementation significantly improved fasting plasma glucose
and HbA1c (glycated haemoglobin )levels [24–28].
Similarly, glycaemic control and blood antioxidant levels were significantly improved in type
II diabetics following supplementation (100 mg/day for three months) with the reduced (ubiquinol)
form of CoQ10 [29]. In patients with diabetic neuropathy, supplementation with CoQ10 (200 mg/day
for three months) did not significantly benefit neuropathic symptoms, but reduced inflammation
and increased insulin sensitivity [30]. Supplementation with CoQ10 in metabolic syndrome patients
(100 mg/day for two months, [31]) or obese patients (200 mg/day for three months, [32]) improved
glycaemic control, and in the latter case waist circumference. Yoo and Yum [33] suggested CoQ10
supplementation in patients with impaired glucose tolerance could slow the progression from
pre-diabetes to overt type II diabetes. The benefit of CoQ10 supplementation on glycaemic control and
blood lipid levels has been confirmed in a recent meta-analysis by Zhang et al. [34].
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Supplemental CoQ10 may benefit type II diabetes via several mechanisms, for example by
promoting enhanced levels of cellular energy required for glucose metabolism, or via direct modulation
of the expression of genes relevant to glucose metabolism, or via its antioxidant action [35]. Thus,
supplementation with CoQ10 (100 mg/day for three months) in patients with diabetic nephropathy
significantly reduced inflammation via improved gene expression of peroxisome proliferators activated
receptor gamma, interleukin-1 and tumour necrosis factor alpha [36]. With regard to antioxidant
activity, evidence of increased oxidative stress (correlating with depleted blood CoQ10 levels) was
reported by Ates et al. [37]. Randomised controlled trials supplementing CoQ10 (200 mg/day for three
months) in type II diabetic patients found reduced blood levels of oxidative stress markers, improved
endothelial function/blood flow and reduced cardiovascular risk [38,39]
The use of statins (particularly simvastatin) has been associated with an increased risk of between
10% and 40% of developing type II diabetes [40,41]; this is thought to result from statin-induced
depletions of circulatory levels of CoQ10, adiponectin and glucose transporter-4 (GLUT4) protein [42].
Although CoQ10 administration has been shown to prevent simvastatin induced GLUT4 protein
levels in cell culture [43], Kuhlman et al. [44] failed to find significant changes in muscle GLUT4 levels
following supplementation with CoQ10 (400 mg/day for two months) in simvastatin treated subjects.
4. Chronic Kidney Disease (CKD)
The role of supplemental CoQ10 in chronic kidney disease (CKD) has been reviewed [45], from
which the following information has been summarised. Plasma CoQ10 levels have been reported
to be significantly lower in CKD patients (with or without haemodialysis), compared to normal
controls [46–48]. There is evidence that CoQ10 supplementation may improve renal function and
reduce the need for dialysis in patients with CKD. In a randomised controlled study [49], 97 CKD
patients were given supplementary CoQ10 (3 × 100 mg daily for three months) or placebo. There was
a significant improvement in markers of renal function (e.g., serum creatinine) in CoQ10 supplemented
patients compared to placebo, in both dialysed and non-dialysed patients. In particular, the number
of patients requiring dialysis in the CoQ10 treated group decreased from 21 to 12, whilst remaining
unchanged at 24 in the placebo group. Decreased CoQ10 levels may be a particular issue in CKD
patients prescribed statins, since some studies have reported a deficit in CoQ10 status in association
with this pharmacotherapy in a subset of patients. It has been suggested that these patients may have
some form of underlying mitochondrial disease and therefore may be more susceptible to the adverse
effects of statin therapy [50].
Although haemodialysis is essential for removing uremic toxins, it is a consequence of the
procedure that individuals are subject to additional oxidative stress (a result of neutrophil exposure to
the synthetic material comprising the dialyser membrane), in addition to the oxidative stress associated
with CKD. A number of clinical studies have reported that supplementation with CoQ10 significantly
improves outcome in haemodialysis patients by reducing markers of oxidative stress and inflammation.
In a randomised controlled trial, Zahed et al. [51] reported that CoQ10 supplementation (100 mg/day
for three months) in end stage CKD patients undergoing haemodialysis significantly reduced serum
levels of the inflammatory marker C-reactive protein. An open label dose escalation study by Yeung et
al. [48] showed supplementation with CoQ10 over the range 300–1800 mg/day for 14 days to be safe
and well tolerated, significantly reducing plasma levels of the oxidative stress marker isofuran.
Patients with CKD are at high risk of developing cardiovascular disease, with a 10–20 fold
increased risk of cardiovascular mortality compared to non-CKD individuals. Overall, approximately
50% of deaths in CKD patients result from cardiovascular disease, rather than as a direct consequence
of kidney failure. Conversely, cardiovascular disease can cause CKD leading to a vicious circle in which
each disorder exacerbates the other. Thus, treatment of CKD can reduce the incidence of cardiovascular
disease, and treatment of cardiovascular disease can reduce further deterioration in renal function.
The ratio of plasma CoQ10 versus low density lipoprotein (LDL) cholesterol + VLDL (very low density
lipoprotein) cholesterol, considered to be more important in athersclerosis prevention than the ratio of
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HDL (high density lipoprotein ):LDL cholesterol [52], was significantly lower in CKD patients (with or
without dialysis) compared to controls [53]. A recent meta-analysis by Bakhshayeshkaram et al. [54]
confirmed significant improvement in blood cholesterol, markers of oxidative stress, and creatinine
levels following CoQ10 supplementation in CKD patients.
Epicardial fat thickness, a new risk factor for cardiovascular disease, was found to be significantly
greater in CKD patients undergoing haemodialysis compared to controls and correlated with reduced
plasma CoQ10 levels [55]. Similarly, coronary flow reserve, an indicator of atherosclerosis, was reported
to be significantly lower in haemodialysis patients, correlating inversely with serum CoQ10 levels [55].
5. Liver Disease
Although endogenous CoQ10 synthesis occurs throughout the body, because of its physical size
and high metabolic capacity, the liver is the major site of CoQ10 synthesis. In patients with liver
disease where metabolic capacity has been compromised, a reduction in CoQ10 production is likely to
have a deleterious effect on heart function. Thus, non-alcoholic fatty liver disease (NAFLD) is a risk
factor for cardiovascular disease, which has been reported to be one of the major causes of death in
NAFLD patients [56]. NAFLD is associated with heart failure, arrhythmias, valve dysfunction and
atherosclerosis [57]. Alcohol-related liver disease is similarly associated with an increased risk of
cardiovascular disorders; these include alcoholic cardiomyopathy, arterial hypertension and atrial
fibrilation [58]. Reduced CoQ10 levels may be a particular problem in patients with fatty liver
disease prescribed statins, since in addition to inhibiting cholesterol synthesis, statins also inhibit the
production of CoQ10.
In addition to reducing the risk of cardiovascular problems in patients with liver disease, CoQ10
supplementation may also benefit the disease process within the liver by reducing inflammation and
oxidative stress. For example, one of the principal mechanisms by which alcohol causes liver damage
is via the generation of free radicals, and the antioxidant action of CoQ10 can help to protect liver cells
from such oxidative damage [59]. Free radical induced oxidative stress has similarly been implicated
in the pathogenesis of NAFLD [60].
A number of studies in animal models have demonstrated the ability of CoQ10 to reduce or
prevent the development of liver cirrhosis following a variety of toxic insults; these include exposure
to medicinal drugs [61], toxic chemicals [62] and parasitic microorganisms [63]. For example, in the
study by Fouad and Jresat [60], the ability of CoQ10 to protect liver tissue against free radical induced
oxidative damage was demonstrated; when acute liver injury was induced in rats via administration
of acetaminophen (paracetamol), subsequent administration of CoQ10 reduced cirrhotic tissue damage
via its antioxidant and anti-inflammatory action. Similarly, in rats prone to developing NAFLD,
dietary supplementation with CoQ10 prevented further progression to cirrhosis via downregulation of
markers of free radical induced oxidative stress and inflammation [64].
There have been relatively few clinical studies relating to CoQ10 and liver disease. Evidence for
depleted CoQ10 blood levels in NAFLD patients was reported by Yessilova et al. [65]. Two randomized
controlled clinical trials have been carried out to date supplementing CoQ10 in NAFLD patients;
in both cases, 100 mg/day CoQ10 supplemented for four weeks [66] or 12 weeks [67] respectively
resulted in significant reductions in blood markers for inflammation and liver damage.
6. CoQ10 Supplementation: Importance of Product Quality and Bioavailability
With regard to clinical studies involving oral supplementation with CoQ10, one very important
issue that has received relatively little attention is the question of supplement quality and bioavailability.
Because nutritional supplements are not regulated in the UK in the same way as prescription medicines,
there is no legal quality requirement relating to defined levels of active substances and product stability;
supplements may therefore, for example, contain lower levels of CoQ10 per capsule than stated on the
product packaging. The best way to avoid this problem is therefore to use a CoQ10 supplement that
has been manufactured to pharmaceutical standards.
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There are currently more than 300 randomised controlled clinical trials relating to CoQ10
listed on Medline, including 70 on heart disease, 30 on diabetes, 10 on renal disease and six
on liver disease. Whilst the majority of such studies have reported significant benefit of CoQ10
supplementation (particularly in heart disease), some studies have reported no significant benefit.
Such disparity may result from a number of factors, including insufficient CoQ10 dosage or treatment
duration, and inter-individual variation in the ability to absorb CoQ10, but particularly from
inadequate bioavailability, especially where CoQ10 blood levels have not been determined pre- and
post-supplementation. Because of the molecular characteristics of CoQ10, bioavailability is intrinsically
low. As a lipid soluble substance, bioavailability is optimized via the use of a carrier oil such as
soy oil; however, the key factor in determining bioavailability is the efficient dispersion of CoQ10
crystals formed during the yeast fermentation manufacturing process [68]. Similarly, there are currently
some 40 meta-analyses relating to CoQ10 listed on Medline, including 15 on heart disease and three
on diabetes. Some of these studies have reported a lack of evidence to support the use of CoQ10
supplementation in these various indications; for example, the Cochrane review by Madmani et al. [69]
concluded that there was insufficient evidence to support the use of supplemental CoQ10 in heart
failure, although this study did not include data from the Q-SYMBIO and KiSEL-10 clinical trials.
However, the majority of meta-analyses have reported significant benefit of CoQ10 supplementation
in the above indications; recent examples include those relating to cardiovascular disease [70–72] and
diabetes [73].
Another factor affecting efficacy is the relative bioavailability of the ubiquinone and ubiquinol
forms of CoQ10. Some supplement manufacturers have claimed that the ubiquinol form is more
bioavailable, based on the concept that absorption of CoQ10 into enterocyte cells was thought to
require reduction of ubiquinone to ubiquinol, and presentation of supplemental CoQ10 in ubiquinol
form facilitated this absorption, particularly in patients with malabsorption disorders. However, work
by Judy [74] demonstrated that reduction of ubiquinone to ubiquinol takes place within the lymphatic
system rather than during absorption by enterocytes; in addition, during the time of transit from
the stomach to the small intestine (typically 2–5 h), CoQ10 in reduced form would be oxidised to
ubiquinone, a process taking approximately 80 minutes in simulated gastric conditions [74]. In the
study by Lopez-Lluch et al. [68] in human subjects, the bioavailability of CoQ10 in ubiquinone form,
when properly dispersed in carrier oil, was approximately twice that of the corresponding ubiquinol
form; thus, it is the crystal dispersion status, rather than redox status, of the CoQ10 that essentially
determines bioavailability.
7. Conclusion
In summary, we have reviewed evidence from randomised controlled clinical trials as to how
oral supplementation with CoQ10, either alone or in tandem with selenium, can significantly reduce
mortality risk from cardiovascular disease in normal elderly subjects, or in those with heart failure. In
addition, supplementary CoQ10 may reduce mortality risk in patients with type II diabetes, chronic
kidney disease or liver disease, both by beneficial effects on the primary disease process in these
tissues, or on cardiovascular dysfunction secondary to these disorders.
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